Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil
News release
by
Algernon Pharmaceuticals Inc.
Vancouver, BC
|
January 10, 2023 11:00 AM Pacific Standard Time
Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre-Investigational new drug meeting.
Contact Details
Proactive Canada
Proactive Canada
+1 604-688-8158
